This is a knowledge base for any and all things related to EGFR-positive NSCLC. Where possible and relevant, all information published on this website should include references. References should preferentially be actual embedded copies of papers and presentations, rather than links which can rapidly become out-of-date, or have restricted access.
[In progress - answer should describe both anti-CTLA4 and anti-PD-1/PD-L1 inhibitors.]
  0 votes
  0 answers
  0 comments
  77 views

  0 votes
  0 answers
  0 comments
  99 views

  0 votes
  0 answers
  0 comments
  102 views

  0 votes
  1 answers
  0 comments
  111 views

[WORK IN PROGRESS - DESCRIPTIONS HERE ARE INTENDED TO BE BRIEF. MORE IN-DEPTH DESCRIPTIONS CAN BE ON SEPARATE PAGES, AND LINKED TO FROM HERE.]
  0 votes
  1 answers
  0 comments
  1294 views

  0 votes
  1 answers
  0 comments
  92 views

  0 votes
  1 answers
  0 comments
  167 views

(7 / 7)

Recent Activity

More


Base Managers
Robert Hanlon
Member (20)
Lars Soraas
Member (20)
Aaron Andersen
Member (20)
Marcia Horn
Director, the Exon 20 Group (20)
Mark Sinclair-McGarvie
Member (405)

Quandora Stats
1
Knowledge Bases
7
questions
4
answers
0
active tags
1
active users